Open Access Research article

EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression

Géraldine Lescaille1, Suzanne Menashi2, Bénédicte Cavelier-Balloy3, Farah Khayati1, Cathy Quemener1, Marie Pierre Podgorniak4, Benyoussef Naïmi5, Fabien Calvo16, Céleste Lebbe67 and Samia Mourah1468*

Author Affiliations

1 Inserm, UMR-S 940, Paris F-75010, France

2 CNRS, EAC 7149, Laboratoire CRRET, Université 12, Créteil F-94000, France

3 Cabinet de Dermatopathologie 35, avenue Mathurin Moreau, 75019 Paris, France

4 AP-HP, Hôpital Saint-Louis, Laboratory of Pharmacology, Paris F-75010, France

5 Université Paris 12, Créteil, Paris, France

6 Université Paris 7- IUH, Paris F-75010, France

7 Département de Dermatologie, hôpital Saint Louis, Paris F-75010, France

8 Laboratoire de Pharmacologie and INSERM U940, Hôpital Saint-Louis, 27, rue Juliette Dodu, 75010 Paris, France

For all author emails, please log on.

BMC Cancer 2012, 12:115  doi:10.1186/1471-2407-12-115

Published: 23 March 2012



An elevated level of EMMPRIN in cancer tissues have been correlated with tumor invasion in numerous cancers including oral cavity and larynx. Although EMMPRIN's effect has been generally attributed to its MMP inducing activity, we have previously demonstrated in breast cancer model that EMMPRIN can also enhance invasion by upregulating uPA. In this study, the role of EMMPRIN in regulating uPA and invasion was investigated in oral squamous cell carcinoma (OSCC) progression.


Precancerous and invasive oral tumoral tissues were used as well as the corresponding cell lines, DOK and SCC-9 respectively. The paracrine regulation of uPA by EMMPRIN was investigated by treating culture cells with EMMPRIN-enriched membrane vesicles. UPA expression was analyzed by qPCR and immunostaining and the consequence on the invasion capacity was studied using modified Boyden chamber assay, in the presence or absence of EMMPRIN blocking antibody, the uPA inhibitor amiloride or the MMP inhibitor marimastat.


OSCC tumors were shown to express more EMMPRIN and uPA compared to dysplastic lesions. The corresponding cell models, SCC-9 and DOK cells, displayed similar expression pattern. In both cell types EMMPRIN upregulated the expression of uPA as well as that of MMP-2 and MMP-9. EMMPRIN treatment led to a significant increase in cell invasion both in the invasive SCC-9 and in the less invasive dysplastic DOK cells, in an MMP and uPA dependent manner.


Our results suggest that the upregulation of uPA contributes to EMMPRIN's effect in promoting oral tumor invasion.

EMMPRIN/CD147; uPA; Oral squamous cell carcinoma; Invasion; Progression